Screener
ANI Pharmaceuticals ANIP Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
FAQ
- What is ANI Pharmaceuticals's retained earnings?
- ANI Pharmaceuticals (ANIP) reported retained earnings of $31.1M in Q2 2026.
- How has ANI Pharmaceuticals's retained earnings changed year-over-year?
- ANI Pharmaceuticals's retained earnings increased by 140.5% year-over-year, from -$76.86M to $31.1M.
- What is the long-term trend for ANI Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's retained earnings has grown at a 36.0% compound annual growth rate (CAGR), from -$4.97M to -$23.1M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about ANI Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude